Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Gao, Shuaishuai; Wang, Yanjun; Zhang, Guoxun; Zhang, Wenting

doi:10.1016/j.jbo.2020.100327

Cited by 12 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We updated this meta-analysis to figure out whether the circulating miRNAs could be promising means for early detection of MM with the latest evidence. The pooled sensitivity, specificity, AUC, PLR, NLR, and DOR were 0.79, 0.86, 0.87, 5, 0.27, and 22, respectively, consistent with the previous meta-analysis (10). Summary LRP and LRN for Index Test suggest a small number of studies have relatively high value for diagnosis conformation and/or exclusion.…”

Section: Discussionsupporting

confidence: 87%

“…However, the quality assessment of literatures presents a few ignorable flaws and uncertainties, which are somewhat inconsistent with the results of the previous meta-analysis (10), possibly because of the different versions of evaluation tools or the strictness in our assessment. We found that some of the literatures did not specify the study design, patient information (stage/Ig isotype/treatment information), or the time interval between the reference standard and miRNA detection.…”

Section: Discussionmentioning

confidence: 72%

“…In comparison to the previous version of review ( 10 ), one report of a study for non-circulating specimen ( 12 ) and seven reports of four articles published in Chinese were excluded; and one report of a new study was included ( 13 ). The main information of circulating miRNA reports extracted from the qualified studies is displayed in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Total diagnostic accuracy was assessed by summary receiver operating characteristic (SROC) curve with the sensitivity and specificity data of each qualified study. To evaluate the existence of heterogeneity, I 2 over 50% and/or P-value of Q-test under 0.05 In comparison to the previous version of review (10), one report of a study for non-circulating specimen (12) and seven reports of four articles published in Chinese were excluded; and one report of a new study was included (13). The main information of circulating miRNA reports extracted from the qualified studies is displayed in Table 1.…”

Section: Discussionmentioning

confidence: 99%

“…Circulating miRNAs have been explored as valuable tools for various tumor diagnoses and prognoses by several studies ( 8 ). Similarly, the diversification of circulating miRNA expression in MM has been investigated, indicating that miRNAs could serve as potential diagnostic biomarkers ( 9 , 10 ). However, not every miRNA was eligible, and there was significant heterogeneity among the findings.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematologic malignancy characterized by aberrant expansion of monoclonal plasma cells with high mortality and severe complications due to the lack of early diagnosis and timely treatment. Circulating miRNAs have shown potential in the diagnosis of MM with inconsistent results, which remains to be fully assessed. Here we updated a meta-analysis with relative studies and essays published in English before Jan 31, 2021. After steps of screening, 32 studies from 11 articles that included a total of 627 MM patients and 314 healthy controls were collected. All data were analyzed by REVMAN 5.3 and Stata MP 16, and the quality of included literatures was estimated by Diagnostic Accuracy Study 2 (QUADAS-2). The pooled area under the curve (AUC) shown in summary receiver operating characteristic (SROC) analyses of circulating miRNAs was 0.87 (95%CI, 0.81–0.89), and the sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were 0.79, 0.86, 5, 0.27, 22, respectively. Meta-regression and subgroup analysis exhibited that “miRNA cluster”, patient “detailed stage or Ig isotype” accounted for a considerable proportion of heterogeneity, revealing the importance of study design and patient inclusion in diagnostic trials; thus standardized recommendations were proposed for further studies. In addition, the performance of the circulating miRNAs included in MM prognosis and treatment response prediction was summarized, indicating that they could serve as valuable biomarkers, which would expand their clinical application greatly.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=234297, PROSPERO, identifier (CRD42021234297).

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 72%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

et al. 2021

View full text Add to dashboard Cite

show abstract

Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers

Prasad

Prabhavathi

Sushma

et al. 2022

Role of MicroRNAs in Cancers

View full text Add to dashboard Cite

Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment

2022

View full text Add to dashboard Cite

Multiple myeloma (MM) is an incurable plasma cell malignancy, which is predominantly a disease of older adults (the median age at diagnosis is 70 years). The slow progression from asymptomatic stages and the late-onset of MM suggest fundamental differences compared to many other hematopoietic system-related malignancies. The concept discussed in this review is that age-related changes at the level of terminally differentiated plasma cells act as the main risk factors for the development of MM. Epigenetic and genetic changes that characterize both MM development and normal aging are highlighted. The relationships between cellular aging processes, genetic mosaicism in plasma cells, and risk for MM and the stochastic processes contributing to clonal selection and expansion of mutated plasma cells are investigated. In line with the DNA damage accumulation theory of aging, in this review, the evolution of monoclonal gammopathy to symptomatic MM is considered. Therapeutic consequences of age-dependent comorbidities that lead to frailty and have fundamental influence on treatment outcome are described. The importance of considering geriatric states when planning the life-long treatment course of an elderly MM patient in order to achieve maximal therapeutic benefit is emphasized.

show abstract

Potential diagnostic value of circulating miRNA for multiple myeloma: A meta-analysis

Abstract: Highlights This meta-analysis is a comprehensively studies of microRNA in MM. MicroRNA clusters helped to distinguish MM and healthy people. MicroRNA is a potential noninvasive biomarker in early diagnosis of MM.

Cited by 12 publications

References 38 publications

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations

Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers

Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment

Contact Info

Product

Resources

About